Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics, Inc. (LENZ) Liabilities and Shareholders Equity (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $266.2 million as the latest value for Q3 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 20.49% to $266.2 million in Q3 2023 year-over-year; TTM through Dec 2023 was $863.3 million, a 37.86% decrease, with the full-year FY2022 number at $321.9 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $266.2 million for Q3 2023 at LENZ Therapeutics, down from $287.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $378.6 million in Q1 2022 to a low of $266.2 million in Q3 2023.